Nabriva Therapeutics Plc logo

Nabriva Therapeutics Plc(OTC) NBRVF

Market Cap$300.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-100%
5 Year-100%
1 Year+0%
1 Month+0%
$0.00
+0.00%
+0.00Today
Nabriva Therapeutics Plc last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-13
Nabriva Therapeutics Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-08-03
1 month+0%USD 0.002026-06-15
3 month+0%USD 0.002026-05-15
Year to date+0%USD 0.002025-12-31
1 year+0%USD 0.002025-08-13
3 year-99.99%USD 0.832023-08-14
5 year-100%USD 26.002021-08-13
Since inception-100%USD 3,310.002015-09-18

Nabriva Therapeutics Plc Financials at a Glance

Market Cap

$300.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$29.39M

Net Income (TTM)

-$55.05M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-229.16 (Low)

Price

$0.00

Volume

12

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Aug 31, 2026

NBRVF News

Falling_Stock_Chart

Why Nabriva Therapeutics Stock Is Falling Today

Brian FeroldiMay 21, 2018
Scientist looking at microscope cancer research

3 Companies Tackling the Antibiotic-Resistant Bacteria Crisis

Brian FeroldiOct 26, 2017
Businessman with coins falling through his hands

Why Nabriva Therapeutics Shares Are Falling Today

Brian FeroldiSep 20, 2017
businessmen looking over a contract

Here's Why Nabriva Therapeutics PLC Is Soaring Today

Brian FeroldiSep 19, 2017
A group of doctors cheering

Why Nabriva Therapeutics PLC Is Skyrocketing

Brian FeroldiSep 18, 2017

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nabriva Therapeutics Plc

Nabriva Therapeutics plc is a biopharmaceutical company dedicated to developing innovative anti-infective medications aimed at treating serious infections. The company markets SIVEXTRO and XENLETA, with ongoing research into additional applications for XENLETA and the development of CONTEPO.

Products and Services
  • SIVEXTRO for acute bacterial skin infections
  • XENLETA for community-acquired bacterial pneumonia
  • CONTEPO for complicated urinary tract infections in development
Growth Outlook
  • Ongoing Phase I trials for XENLETA in various indications
  • Potential expansion into pediatric and cystic fibrosis markets
  • Focus on addressing unmet needs in anti-infective therapies
Financial Highlights
  • Q1 2023 revenue of $7.59 million, showing growth from previous quarters
  • Net income for Q1 2023 was -$8.7 million, reflecting ongoing investment in R&D
  • Cash and cash equivalents at $1.8 million as of March 31, 2023
Nabriva Therapeutics is positioned in the biotechnology sector, focusing on critical areas of healthcare. The company’s current products address significant medical needs, while its research pipeline indicates a commitment to innovation. Recent financial data shows a revenue increase in the latest quarter, although the company continues to operate at a loss as it invests heavily in research and development. The ongoing trials and potential market expansions could provide future growth opportunities, making Nabriva an intriguing option for investors interested in the biotechnology field.
AI Generated • Sep 19, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

39

CEO

Theodore R. Schroeder

Website

www.nabriva.com

Headquarters

Dublin, DU 4, IE

NBRVF Financials

Key Financial Metrics (TTM)

Gross Margin

19.87%

Operating Margin

-155.57%

Net Income Margin

-160.33%

Return on Equity

-201.91%

Return on Capital

-651.75%

Return on Assets

-180.03%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$300.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.23M

Volume

12

Avg. Volume

0.25

Financials (TTM)

Gross Profit

-$4.89M

Operating Income

-$54.03M

EBITDA

-$53.61M

Operating Cash Flow

-$12.91M

Capital Expenditure

-$115.02K

Free Cash Flow

-$13.02M

Cash & ST Invst.

$2.18M

Total Debt

$540.00K

Nabriva Therapeutics Plc Performance Analysis

Nabriva Therapeutics Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 28,895,000N/A
20222022-12-31USD 36,935,00027.8%
Nabriva Therapeutics Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32022-09-300.1%
Q42022-12-3118.8%
Q12023-03-31-27.3%
Q22023-06-30-66.1%
Nabriva Therapeutics Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -28.52N/A
20222022-12-31USD -21.32-25.2%
Nabriva Therapeutics Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32022-09-303.9%
Q42022-12-31-73.9%
Q12023-03-3162.8%
Q22023-06-30-37.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2023YOY CHG

Revenue

$2.57M

-70.7%

Gross Profit

-$6.50M

-250.4%

Gross Margin

-2.53%

N/A

Market Cap

$300.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$7.69

N/A

Employees

39

N/A

Net Income

-$12.06M

-8.9%

EBITDA

-$12.01M

-16.3%

Quarterly Fundamentals

Name
Q2 2023YOY CHG

Total Cash

$2.18M

-89.1%

Total Debt

$540.00K

-92.4%

Accounts Receivable

$4.44M

-64.1%

Inventory

$0.00

-100.0%

Long Term Debt

$344.00K

-32.8%

Short Term Debt

$196.00K

-97.0%

Return on Assets

-1.80%

N/A

Return on Invested Capital

-13.34%

N/A

Free Cash Flow

$511.00K

+103.9%

Operating Cash Flow

$511.00K

+103.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NMTRQ9 Meters Biopharma, Inc.
$0.00+0.00%
GMVDFG Medical Innovations Holdings Ltd
$0.00+0.00%
EVFMEvofem Biosciences, Inc.
$0.01+3.90%
HEPAHepion Pharmaceuticals, Inc.
$0.10-9.09%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$118.67+2.36%
BITOProShares Trust - ProShares Bitcoin ETF
$11.26+0.45%
NVDANvidia
$230.67+1.52%
SPCXSpace Exploration Technologies
$150.62+0.93%

Questions About NBRVF

What is the current price of Nabriva Therapeutics Plc?

Nabriva Therapeutics Plc is trading at $0.00 per share.

What is the 52-week range for Nabriva Therapeutics Plc?

Over the past 52 weeks, Nabriva Therapeutics Plc has traded between $0.00 and $0.00.

How much debt does Nabriva Therapeutics Plc have?

As of the most recent reporting period, Nabriva Therapeutics Plc reported total debt of $5.22M.

How much cash does Nabriva Therapeutics Plc have on hand?

Nabriva Therapeutics Plc reported $12.54M in cash and cash equivalents in its most recent financial results.

What is Nabriva Therapeutics Plc’s dividend yield?

Nabriva Therapeutics Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services